We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
EyePoint (EYPT) Gets FDA Approval for Eye Therapy Yutiq
Read MoreHide Full Article
EyePoint Pharmaceuticals, Inc. (EYPT - Free Report) announced that the FDA has approved Yutiq (fluocinolone acetonide intravitreal implant) for treating chronic non-infectious uveitis affecting the posterior section of the eye.
Yutiq is a tiny micro-insert that utilizes EyePoint’s Durasert drug delivery technology, containing 0.18 mg fluocinolone acetonide, designed to release consistently over a period of 36 months and is the first long-lasting micro-insert to be approved by the FDA.
The nod was based on clinical data from two phase III randomized, sham injection-controlled, clinical studies with patient follow-up continuing for three years. Both evaluations met the primary efficacy endpoint of preventing recurrent uveitis flares after six and 12 months. The analyses demonstrated that Yutiq considerably reduced the rate of recurrent uveitis flares.
EyePoint expects to report the 24-month and 36-month patient follow-up from the first phase III clinical study on Yutiq by the end of 2018 and the first half of 2019, respectively.
Notably, in March 2018, the FDA accepted EyePoint’s New Drug Application (NDA) for Yutiq and set an action date of Nov 5, 2018. However, this approval comes before the stipulated time and is a great boost to the company. EyePoint plans to launch Yutiq in the United States during the first quarter of 2019.
The company is also designing a next-generation, shorter-duration treatment for the same indication, based on the Durasert drug delivery technology. The company plans to file an application for this insert next year.
However, EyePoint is likely to face stiff competition from the already available products approved for the given indication. AbbVie's (ABBV - Free Report) Humira and Allergan’s Ozurdex are approved for a similar disease.
The company currently has strategic collaboration with Alimera Sciences (ALIM - Free Report) and several other pharma companies.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
EyePoint (EYPT) Gets FDA Approval for Eye Therapy Yutiq
EyePoint Pharmaceuticals, Inc. (EYPT - Free Report) announced that the FDA has approved Yutiq (fluocinolone acetonide intravitreal implant) for treating chronic non-infectious uveitis affecting the posterior section of the eye.
Yutiq is a tiny micro-insert that utilizes EyePoint’s Durasert drug delivery technology, containing 0.18 mg fluocinolone acetonide, designed to release consistently over a period of 36 months and is the first long-lasting micro-insert to be approved by the FDA.
The nod was based on clinical data from two phase III randomized, sham injection-controlled, clinical studies with patient follow-up continuing for three years. Both evaluations met the primary efficacy endpoint of preventing recurrent uveitis flares after six and 12 months. The analyses demonstrated that Yutiq considerably reduced the rate of recurrent uveitis flares.
EyePoint expects to report the 24-month and 36-month patient follow-up from the first phase III clinical study on Yutiq by the end of 2018 and the first half of 2019, respectively.
Notably, in March 2018, the FDA accepted EyePoint’s New Drug Application (NDA) for Yutiq and set an action date of Nov 5, 2018. However, this approval comes before the stipulated time and is a great boost to the company. EyePoint plans to launch Yutiq in the United States during the first quarter of 2019.
The company is also designing a next-generation, shorter-duration treatment for the same indication, based on the Durasert drug delivery technology. The company plans to file an application for this insert next year.
However, EyePoint is likely to face stiff competition from the already available products approved for the given indication. AbbVie's (ABBV - Free Report) Humira and Allergan’s Ozurdex are approved for a similar disease.
The company currently has strategic collaboration with Alimera Sciences (ALIM - Free Report) and several other pharma companies.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>